Hans Klingemann - Concepedia

Author

Hans Klingemann

Also Known As

Curtis Cetrulo, H G Klingemann, H Klingemann, H. Klingemann, H.-G. Klingemann, H.G. Klingemann, HANS G. KLINGEMANN, Hans G Klingemann, Hans G. Klingemann, Hans Klingemann

100

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

ImmunityBio (United States)Tufts Medical Center Georg Speyer Haus Rush University Medical Center Goethe University Frankfurt

About

Hans Klingemann is an author at ImmunityBio (United States) specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	2.7K
2	Health Sciences	2	2	236
3	Allergy	2	2	156
4	Engineering	1	1	190
5	Biomedical Engineering	1	1	190

Hans Klingemann

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Treatment of patients with advanced cancer with the natural killer cell line NK-92 Torsten Tonn, Dirk Schwabe, Hans Klingemann, Cytotherapy Lymphoid NeoplasiaAdvanced CancerCell TherapyCancer ImmunosurveillanceMedicine	2013	461
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial Sally Arai, Richard Meagher, Michelle L. Swearingen, Cytotherapy Cancer ImmunosurveillanceGenitourinary CancerImmunotherapyMedicineImmunology	2008	423
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor Kurt Schönfeld, Christiane Sahm, Congcong Zhang, Molecular Therapy	2014	337
Are natural killer cells superior CAR drivers? Hans Klingemann OncoImmunology Chimeric Antigen ReceptorCell TherapyCancer ImmunosurveillanceAutoimmune DiseaseImmunology	2014	263
<scp>CD</scp>19‐<scp>CAR</scp> engineered <scp>NK</scp>‐92 cells are sufficient to overcome <scp>NK</scp> cell resistance in B‐cell malignancies A Romański, Christoph Uherek, Gesine Bug, Journal of Cellular and Molecular Medicine	2016	220
Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia Damiano Rondelli, Giovanni Barosi, Andrea Bacigalupo, Blood	2005	200
Characterization of Genetically Altered, Interleukin 2-Independent Natural Killer Cell Lines Suitable for Adoptive Cellular Immunotherapy Ying K. Tam, Guitta Maki, Blythe Miyagawa, Human Gene Therapy	1999	198
Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity Laurent Boissel, Monica Betancur, Weiquan Lu, OncoImmunology	2013	190
Umbilical Cord Mesenchymal Stem Cells: Adjuvants for Human Cell Transplantation Robb S. Friedman, Monica Betancur, Laurent Boissel, Biology of Blood and Marrow Transplantation Tissue EngineeringEngineeringBiomedical EngineeringHuman Cell TransplantationRegenerative Medicine	2007	190
Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma Sarah Oelsner, Miriam E. Friede, Congcong Zhang, Cytotherapy B-cell LeukemiaCar Nk-92 CellsLymphoid NeoplasiaImmunologySelective Cytotoxicity	2016	186

Page 1